Abstract
In human T-lymphocytes, the voltage-gated Kv1.3 channel and the Ca 2+-activated IKCa1 channel play an important role in Ca2+ signaling, activation, adhesion and migration and have, therefore, long been regarded as attractive targets for immunotherapy. Here, we review the pharmacology of the two channels, their expression pattern in naïve and memory T-cells and their functional roles during T-cell activation, and explain the rationale for the use of Kv1.3 blockers for the therapy of T-cell mediated autoimmune diseases.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 640-647 |
| Number of pages | 8 |
| Journal | Current Opinion in Drug Discovery and Development |
| Volume | 6 |
| Issue number | 5 |
| State | Published - Sep 2003 |
Fingerprint
Keywords
- Effector memory T-cells
- IKCa1
- Immunosuppression
- Kv1.3
- Multiple sclerosis
ASJC Scopus subject areas
- Molecular Medicine
- Pharmacology
- Drug Discovery
Cite this
Potassium channels as therapeutic targets for autoimmune disorders. / Wulff, Heike; Beeton, Christine; Chandy, K. George.
In: Current Opinion in Drug Discovery and Development, Vol. 6, No. 5, 09.2003, p. 640-647.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Potassium channels as therapeutic targets for autoimmune disorders
AU - Wulff, Heike
AU - Beeton, Christine
AU - Chandy, K. George
PY - 2003/9
Y1 - 2003/9
N2 - In human T-lymphocytes, the voltage-gated Kv1.3 channel and the Ca 2+-activated IKCa1 channel play an important role in Ca2+ signaling, activation, adhesion and migration and have, therefore, long been regarded as attractive targets for immunotherapy. Here, we review the pharmacology of the two channels, their expression pattern in naïve and memory T-cells and their functional roles during T-cell activation, and explain the rationale for the use of Kv1.3 blockers for the therapy of T-cell mediated autoimmune diseases.
AB - In human T-lymphocytes, the voltage-gated Kv1.3 channel and the Ca 2+-activated IKCa1 channel play an important role in Ca2+ signaling, activation, adhesion and migration and have, therefore, long been regarded as attractive targets for immunotherapy. Here, we review the pharmacology of the two channels, their expression pattern in naïve and memory T-cells and their functional roles during T-cell activation, and explain the rationale for the use of Kv1.3 blockers for the therapy of T-cell mediated autoimmune diseases.
KW - Effector memory T-cells
KW - IKCa1
KW - Immunosuppression
KW - Kv1.3
KW - Multiple sclerosis
UR - http://www.scopus.com/inward/record.url?scp=0142059887&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0142059887&partnerID=8YFLogxK
M3 - Article
C2 - 14579513
AN - SCOPUS:0142059887
VL - 6
SP - 640
EP - 647
JO - Current Opinion in Drug Discovery and Development
JF - Current Opinion in Drug Discovery and Development
SN - 1367-6733
IS - 5
ER -